Carbonic Anhydrase Antagonism in Subarachnoid Hemorrhage
Status:
Withdrawn
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Subarachnoid Hemorrhage (SAH) can occur commonly in the setting of trauma or brain aneurysm.
SAH accounts for 10% of all the strokes. Aneurysmal SAH accounts for 80 % of cases of
non-traumatic cases of SAH, 6-8% of all strokes and 22-25% of all cerebrovascular deaths.
Mortality can be 50% in the first few years of aneurysmal SAH rupture, 15% are severely
disabled post SAH and only 20-35% having a moderate to good recovery it has gained lot of
attention and pre-clinical and clinical trials of various agents have been tried to prevent
poor outcome. The United States epidemiology data reveals the fact that 1% to 5% of adults
have unruptured brain aneurysm and 30,000 people suffer from aneurysm rupture annually
translating to brain aneurysm rupture every 18 minutes.
Vasospasm is the most common SAH complication post 24 hours. It is the segmental or diffuse
narrowing of the vessels especially the large vessels. Fifty percent of those patients who
develop clinical vasospasm, progress to infarction and 15-20% will advance to disabling
stroke or die of cerebral ischemia. The present treatment modalities are insufficient to
prevent vasospasm. So, we need new treatment modalities to decrease the mortality and
morbidity in SAH patients.
The investigators hypothesize that Acetazolamide administration can prevent development of
vasospasm after aneurysmal SAH.